U.S. markets close in 5 hours 29 minutes

Homology Medicines, Inc. (FIXX)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
9.61+0.01 (+0.10%)
As of 10:30AM EST. Market open.

Homology Medicines, Inc.

One Patriots Park
Bedford, MA 01730
United States
781 301 7277

Full Time Employees206

Key Executives

NameTitlePayExercisedYear Born
Dr. Arthur O. TzianabosPres, CEO & Director845.78kN/A1963
Mr. W. Bradford SmithCFO, Treasurer & Sec.552.76kN/A1956
Dr. Albert Seymour Ph.D.Chief Scientific Officer581.07kN/A1968
Dr. Saswati ChatterjeeCo-Founder & Chair of Scientific Advisory BoardN/AN/AN/A
Mr. Timothy P. KellyChief Technical Operations OfficerN/AN/A1969
Dr. Paul Alloway J.D., Ph.D.Sr. VP & Gen. CounselN/AN/AN/A
Ms. Theresa McNeelyChief Communications Officer & Patient AdvocateN/AN/A1964
Ms. Melissa GelorminiVP of HRN/AN/AN/A
Dr. Gabriel M. Cohn M.B.A., M.D.Chief Medical OfficerN/AN/A1959
Mr. Michael Blum M.B.A.Sr. VP of CommercialN/AN/AN/A
Amounts are as of December 31, 2019 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Homology Medicines, Inc., a genetic medicines company, focuses on transforming the lives of patients suffering from rare genetic diseases. Its proprietary platform is designed to utilize its human hematopoietic stem cell derived adeno-associated virus vectors (AAVHSCs) to deliver genetic medicines in vivo either through a gene therapy or nuclease-free gene editing across a range of genetic disorders. The company's various set of AAVHSCs allows company to target, through a single injection, a range of disease-relevant tissues, including the liver, central nervous system, peripheral nervous system, bone marrow, muscle, and eye. Its lead product candidate is HMI-102, which is in Phase 1/2 pheNIX clinical trial, a gene therapy for the treatment of phenylketonuria (PKU) in adults. The company also develops HMI-103 for the treatment of PKU in pediatric patients; and HMI-202 to treat metachromatic leukodystrophy. Homology Medicines, Inc. was founded in 2015 and is based in Bedford, Massachusetts.

Corporate Governance

Homology Medicines, Inc.’s ISS Governance QualityScore as of November 1, 2019 is 7. The pillar scores are Audit: 2; Board: 7; Shareholder Rights: 8; Compensation: 8.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.